Drug Profile
Research programme: diabetes therapy - Prosidion
Alternative Names: DIVA; PSN-IV/119-1Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Prosidion
- Class Antihyperglycaemics
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in United Kingdom (PO)
- 16 Jun 2009 Preclinical trials in Diabetes mellitus in United Kingdom (PO)